Nichols & Pratt Advisers’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,050
| Closed | -$333K | – | 105 |
|
|
2024
Q3 | $333K | Hold |
5,050
| – | – | 0.02% | 90 |
|
|
2024
Q2 | $466K | Hold |
5,050
| – | – | 0.03% | 77 |
|
|
2024
Q1 | $483K | Hold |
5,050
| – | – | 0.03% | 81 |
|
|
2023
Q4 | $385K | Hold |
5,050
| – | – | 0.03% | 86 |
|
|
2023
Q3 | $350K | Hold |
5,050
| – | – | 0.03% | 89 |
|
|
2023
Q2 | $476K | Hold |
5,050
| – | – | 0.03% | 85 |
|
|
2023
Q1 | $418K | Hold |
5,050
| – | – | 0.03% | 85 |
|
|
2022
Q4 | $377K | Hold |
5,050
| – | – | 0.03% | 81 |
|
|
2022
Q3 | $417K | Hold |
5,050
| – | – | 0.04% | 78 |
|
|
2022
Q2 | $480K | Hold |
5,050
| – | – | 0.04% | 78 |
|
|
2022
Q1 | $594K | Hold |
5,050
| – | – | 0.04% | 80 |
|
|
2021
Q4 | $654K | Sell |
5,050
-800
| -14% | -$93.3K | 0.05% | 75 |
|
|
2021
Q3 | $657K | Hold |
5,850
| – | – | 0.05% | 76 |
|
|
2021
Q2 | $606K | Hold |
5,850
| – | – | 0.05% | 77 |
|
|
2021
Q1 | $489K | Hold |
5,850
| – | – | 0.04% | 79 |
|
|
2020
Q4 | $534K | Hold |
5,850
| – | – | 0.04% | 79 |
|
|
2020
Q3 | $467K | Hold |
5,850
| – | – | 0.04% | 76 |
|
|
2020
Q2 | $404K | Sell |
5,850
-750
| -11% | -$53.3K | 0.04% | 80 |
|
|
2020
Q1 | $415K | Hold |
6,600
| – | – | 0.04% | 77 |
|
|
2019
Q4 | $513K | Hold |
6,600
| – | – | 0.04% | 80 |
|
|
2019
Q3 | $484K | Hold |
6,600
| – | – | 0.04% | 84 |
|
|
2019
Q2 | $406K | Hold |
6,600
| – | – | 0.03% | 89 |
|
|
2019
Q1 | $421K | Hold |
6,600
| – | – | 0.04% | 88 |
|
|
2018
Q4 | $337K | Hold |
6,600
| – | – | 0.03% | 89 |
|
|
2018
Q3 | $383K | Hold |
6,600
| – | – | 0.03% | 94 |
|
|
2018
Q2 | $320K | Hold |
6,600
| – | – | 0.03% | 97 |
|
|
2018
Q1 | $307K | Hold |
6,600
| – | – | 0.03% | 99 |
|
|
2017
Q4 | $248K | Hold |
6,600
| – | – | 0.02% | 103 |
|
|
2017
Q3 | $240K | Hold |
6,600
| – | – | 0.02% | 99 |
|
|
2017
Q2 | $260K | Hold |
6,600
| – | – | 0.02% | 97 |
|
|
2017
Q1 | $207K | Hold |
6,600
| – | – | 0.02% | 104 |
|
|
2016
Q4 | $206K | Hold |
6,600
| – | – | 0.02% | 104 |
|
|
2016
Q3 | $265K | Hold |
6,600
| – | – | 0.02% | 99 |
|
|
2016
Q2 | $219K | Buy |
+6,600
| New | +$226K | 0.02% | 112 |
|
Other funds holding EW
Nichols & Pratt Advisers's EW Position: Q4 2024 in Review
Nichols & Pratt Advisers sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 5,050 shares — an estimated $333K sold.
Nichols & Pratt Advisers first reported a position in EW in Q2 2016 and held it in 34 quarters. The position peaked at $657K in Q3 2021. 1,229 funds tracked by Wall St. Rank hold EW as of Q4 2024.
- Nichols & Pratt Advisers reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
- Nichols & Pratt Advisers sold 5,050 Edwards Lifesciences shares in Q4 2024, an estimated $333K.
- Nichols & Pratt Advisers first reported a position in Edwards Lifesciences in Q2 2016 and held it in 34 quarters.
- Nichols & Pratt Advisers's Edwards Lifesciences position peaked at $657K in Q3 2021.
- 1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.
Based on Nichols & Pratt Advisers's 13F filing for Q4 2024, filed 5 Feb 2025.